Drug intelligence / Profile preview

IMC-3253

Development stage: Preclinical
Lead developer: ImmuneCyte Life Sciences
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

IMC-3253 is an investigational chimeric antigen receptor T-cell (CAR-T) therapy being developed by ImmuneCyte Life Sciences for the treatment of multiple myeloma. As a cell-based immunotherapy, it involves the genetic modification of a patient's T cells to express a receptor that targets specific antigens found on the surface of myeloma cells. Once re-infused into the patient, these engineered cells are intended to recognize and eliminate malignant plasma cells. The program is currently in the preclinical or pilot stage of development, utilizing ImmuneCyte's cell therapy platform to address the needs of patients with relapsed or refractory multiple myeloma.

Beyond the preview

Go deeper on IMC-3253.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMC-3253.

Explore the full profile